Loading…
Legislative Progress
Introduced
February 28, 2023
Latest Action
February 28, 2023
Primary Sponsor
David SchweikertRepublican(AZ)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (23)
Referred to the House Committee on Ways and Means.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2026 · first_quarter · Health Issues
S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: H.R. 1492, Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025. To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Section 340B Public Health Services Act 340B engagement and MFN related engagement Provisions related to the 340B program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements Biopharmaceutical innovation and pricing issues HR 5509, Safe Step Act, Provisions related step therapy protocols Tariff and MFN issues VICP Bill
Client expense: $1,640,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2026 · first_quarter · Health Issues
S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues SECURE Rx Act of 2026 (draft) User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (Public Law No. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements
2025 · fourth_quarter · Pharmacy
S.864, Help Ensure Lower Patient (HELP) Copays Act H.R.1509/S.752, Accelerating Kids Access to Care Act H.R.8702/S.4532, Improving Seniors Timely Access to Care Act (118th Congress) H.R.1532/S.822, Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1262/S.932, Give Kids a Chance Act H.R.1990, American Innovation and R&D Competitiveness Act H.R.1414, Camerons Law
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Health Issues
S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 2710: Open Payments Expansion Act S. 3345: PBM Price Transparency and Accountability Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements
2025 · third_quarter · Health Issues
H.R. 7384/S. 4583, the Creating Hope Reauthorization Act of 2024 (118th Congress) H.R. 1509/S. 752 the Accelerating Kids Access to Care Act H.R. 1262/S. 932 - Give Kids a Chance Act of 2025 General discussions about ultra-rare disease drug development General discussions about regulatory reform, including scientific-focused drug development meetings H.R. 1092/S. 526, the BENEFIT Act (118th Congress) General discussions about mitochondrial diseases H.R. 1532/S. 822, the Scientific EXPERT Act of 2025 General discussions about ultra-rare diseases FDA Rare Disease Innovation Hub ORPHAN Cures Act (H.R. 946 / S. 1862) [part of One, Big, Beautiful Bill Act (H.R 1)] Fiscal Year 2026 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R. 4121 / S. 2256)
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| AL |
| Troy E. Nehls | Republican | TX |
| Wesley Hunt | Republican | TX |
Client expense: $12,210,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $8,410,000 · Firm income: Not reported
Government targets: Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Health Issues
S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Acccess to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Give Kids a Chance Act of 2025 H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 2821: FDA Modernization Act 3.0 H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance (AMR) policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements
Client expense: $9,030,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Pharmacy
S.864, Help Ensure Lower Patient (HELP) Copays Act H.R.1509/S.752, Accelerating Kids Access to Care Act H.R.8702/S.4532, Improving Seniors Timely Access to Care Act (118th Congress) H.R.1532/S.822, Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1262/S.932, Give Kids a Chance Act H.R.1990, American Innovation and R&D Competitiveness Act H.R.1414, Camerons Law
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Health Issues
H.R. 7384/S. 4583, the Creating Hope Reauthorization Act of 2024 (118th Congress) H.R. 1509/S. 752 the Accelerating Kids Access to Care Act H.R. 1262/S. 932 - Give Kids a Chance Act of 2025 General discussions about ultra-rare disease drug development General discussions about regulatory reform, including scientific-focused drug development meetings H.R. 1092/S. 526, the BENEFIT Act (118th Congress) General discussions about mitochondrial diseases H.R. 1532/S. 822, the Scientific EXPERT Act of 2025 General discussions about ultra-rare diseases FDA Rare Disease Innovation Hub ORPHAN Cures Act (H.R. 946 / S. 1862) [part of One, Big, Beautiful Bill Act (H.R 1)] Fiscal Year 2026 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R. 4121 / S. 2256)
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Pharmacy
S.864, Help Ensure Lower Patient (HELP) Copays Act H.R.1509/S.752, Accelerating Kids Access to Care Act H.R.8702/S.4532, Improving Seniors Timely Access to Care Act (118th Congress) H.R.1532/S.822, Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1262/S.932, Give Kids a Chance Act H.R.1990, American Innovation and R&D Competitiveness Act H.R.1414, Camerons Law
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Health Issues
H.R. 7384/S. 4583, the Creating Hope Reauthorization Act of 2024 (118th Congress) H.R. 1509/S. 752 the Accelerating Kids Access to Care Act H.R. 1262/S. 932 - Give Kids a Chance Act of 2025 General discussions about ultra-rare disease drug development General discussions about regulatory reform, including scientific-focused drug development meetings H.R. 1092/S. 526, the BENEFIT Act (118th Congress) General discussions about mitochondrial diseases H.R. 1532/S. 822, the Scientific EXPERT Act of 2025 General discussions about ultra-rare diseases FDA Rare Disease Innovation Hub
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Pharmacy
S.864, Help Ensure Lower Patient (HELP) Copays Act H.R.1509/S.752, Accelerating Kids Access to Care Act H.R.8702/S.4532, Improving Seniors Timely Access to Care Act (118th Congress) H.R.1532/S.822, Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1262/S.932, Give Kids a Chance Act H.R.1990, American Innovation and R&D Competitiveness Act H.R.1414, Camerons Law
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Energy/Nuclear
Issues related to direct air capture; H.R.3982/S.5167 - Methane Reduction and Economic Growth Act; H.R.1262/S.542 - CCU Parity Act of 2023.
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Energy/Nuclear
- CCU Parity Act of 2023S. 542/H.R. 1262 Senate/House - Critical Mineral Independence Act of 2023S. 2031 Senate - Critical Minerals Security Act of 2024S. 3631/H.R. 7662 Senate/House - Inflation Reduction ActH.R. 5376 House/Senate/DOE/DOL - Infrastructure Investment and Jobs ActH.R. 3684 House/Senate/DOE/DOL - Intergovernmental Critical Minerals Task Force Act of 2023S. 1871 Senate - Lower Energy Costs ActH.R. 1 House - Mining Schools Act of 2023S. 912 Senate - North American Transatlantic Resource Security Partnership Act of 2023 - S. 458 Senate - ONSHORE Manufacturing Act of 2023S. 44 Senate - PROVE IT Act of 2024S. 1863/H.R. 8623 Senate/House - Permitting for Mining Needs Act of 2023H.R. 209 House - Securing American Critical Minerals Act of 2023H.R. 5021 House - Securing Americas Critical Minerals Supply ActH.R. 1068 House - Supply Chain Security and Resilience ActH.R. 826 House - Supply CHAINS ActH.R. 763 House - UMWA Energy Transition Initiative No Bill# Senate/House
Client expense: $118,517 · Firm income: Not reported
Government targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
2024 · fourth_quarter · Energy/Nuclear
- CCU Parity Act of 2023S. 542/H.R. 1262 Senate/House - Critical Mineral Independence Act of 2023S. 2031 Senate - Critical Minerals Security Act of 2024S. 3631/H.R. 7662 Senate/House - Inflation Reduction ActH.R. 5376 House/Senate/DOE/DOL - Infrastructure Investment and Jobs ActH.R. 3684 House/Senate/DOE/DOL - Intergovernmental Critical Minerals Task Force Act of 2023S. 1871 Senate - Lower Energy Costs ActH.R. 1 House - Mining Schools Act of 2023S. 912 Senate - North American Transatlantic Resource Security Partnership Act of 2023 - S. 458 Senate - ONSHORE Manufacturing Act of 2023S. 44 Senate - PROVE IT Act of 2024S. 1863/H.R. 8623 Senate/House - Permitting for Mining Needs Act of 2023H.R. 209 House - Securing American Critical Minerals Act of 2023H.R. 5021 House - Securing Americas Critical Minerals Supply ActH.R. 1068 House - Supply Chain Security and Resilience ActH.R. 826 House - Supply CHAINS ActH.R. 763 House - UMWA Energy Transition Initiative No Bill# Senate/House
Client expense: $80,283 · Firm income: Not reported
Government targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
2024 · fourth_quarter · Taxation/Internal Revenue Code
Issues related to permitting, infrastructure, and sustainability; draft legislation regarding alternative fuels, building and construction materials standards, carbon capture and sequestration technology, and carbon pricing. S.1863, PROVE IT Act of 2023; S.542/H.R.1262 CCU Parity Act of 2023; S.3198 Foreign Pollution Fee Act of 2023; S.3439, Concrete and Asphalt Innovation Act; H.R.7685, IMPACT Act.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Environment/Superfund
Issues related to permitting, infrastructure, and sustainability; draft legislation regarding alternative fuels, building and construction materials standards, carbon capture and sequestration technology, and carbon pricing. S.1863, PROVE IT Act of 2023; S.542/H.R.1262 CCU Parity Act of 2023; S.3198 Foreign Pollution Fee Act of 2023; S.3439, Concrete and Asphalt Innovation Act; H.R.7685, IMPACT Act.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Manufacturing
Issues related to permitting, infrastructure, and sustainability; draft legislation regarding alternative fuels, building and construction materials standards, carbon capture and sequestration technology, and carbon pricing. S.1863, PROVE IT Act of 2023; S.542/H.R.1262 CCU Parity Act of 2023; S.3198 Foreign Pollution Fee Act of 2023; S.3439, Concrete and Asphalt Innovation Act; H.R.7685, IMPACT Act.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Clean Air and Water (quality)
Issues related to permitting, infrastructure, and sustainability; draft legislation regarding alternative fuels, building and construction materials standards, carbon capture and sequestration technology, and carbon pricing. S.1863, PROVE IT Act of 2023; S.542/H.R.1262 CCU Parity Act of 2023; S.3198 Foreign Pollution Fee Act of 2023; S.3439, Concrete and Asphalt Innovation Act; H.R.7685, IMPACT Act.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Taxation/Internal Revenue Code
Issues related to permitting, infrastructure, and sustainability; draft legislation regarding alternative fuels, building and construction materials standards, carbon capture and sequestration technology, and carbon pricing. S.1863, PROVE IT Act of 2023; S.542/H.R.1262 CCU Parity Act of 2023; S.3198 Foreign Pollution Fee Act of 2023; S.3439, Concrete and Asphalt Innovation Act; H.R.7685, IMPACT Act.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Clean Air and Water (quality)
Issues related to permitting, infrastructure, and sustainability; draft legislation regarding alternative fuels, building and construction materials standards, carbon capture and sequestration technology, and carbon pricing. S.1863, PROVE IT Act of 2023; S.542/H.R.1262 CCU Parity Act of 2023; S.3198 Foreign Pollution Fee Act of 2023; S.3439, Concrete and Asphalt Innovation Act; H.R.7685, IMPACT Act.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Manufacturing
Issues related to permitting, infrastructure, and sustainability; draft legislation regarding alternative fuels, building and construction materials standards, carbon capture and sequestration technology, and carbon pricing. S.1863, PROVE IT Act of 2023; S.542/H.R.1262 CCU Parity Act of 2023; S.3198 Foreign Pollution Fee Act of 2023; S.3439, Concrete and Asphalt Innovation Act; H.R.7685, IMPACT Act.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Environment/Superfund
Issues related to permitting, infrastructure, and sustainability; draft legislation regarding alternative fuels, building and construction materials standards, carbon capture and sequestration technology, and carbon pricing. S.1863, PROVE IT Act of 2023; S.542/H.R.1262 CCU Parity Act of 2023; S.3198 Foreign Pollution Fee Act of 2023; S.3439, Concrete and Asphalt Innovation Act; H.R.7685, IMPACT Act.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Taxation/Internal Revenue Code
Issues related to corporate and international tax; Issues related to the Section 45Q tax credit; S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act of 2023; S. 542/H.R. 1262 Captured Carbon Utilization Parity Act; H.R. 7024, Tax Relief for American Families and Workers Act of 2024.
Client expense: $100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Environment/Superfund
Issues related to sustainable packaging and circular economy, including collection, recycling, end-market development, and claims, including S. 1194 / H.R. 4040 Recycling and Composting Accountability Act and S. 1189 Recycling Infrastructure and Accessibility Act of 2023 / Truth in Labeling Act (Discussion Draft). Issues related to carbon dioxide capture and utilization for food and beverage applications, including S. 542 / H.R. 1262 The Carbon Capture Utilization Parity Act. Issues related to renewable energy permitting including S. 4753 The Energy Permitting Reform Act.
Client expense: $130,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Energy/Nuclear
Issues related to direct air capture; H.R.3982/S.5167 - Methane Reduction and Economic Growth Act; H.R.1262/S.542 - CCU Parity Act of 2023.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Taxation/Internal Revenue Code
Implementation of 45Q tax credit for carbon dioxide utilization; S. 542/H.R. 1262, the CCU Parity Act; lifecycle analysis of carbon dioxide utilization.
Client expense: $70,000 · Firm income: Not reported
Government targets: Energy, Dept of, Internal Revenue Service (IRS)
2024 · fourth_quarter · Natural Resources
Carbon dioxide supply chain and life cycle assessment issues; implementation of the Inflation Reduction Act section 45Q regarding CO2 sequestration; Carbon Capture Utilization Parity Act of 2023 (H.R. 1262 and S. 5402); Enhanced Energy Recovery Act (S. 5212); lifecycle analysis of carbon dioxide utilization.
Client expense: Not reported · Firm income: $70,000
Government targets: Energy, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Treasury, Dept of
2024 · fourth_quarter · Taxation/Internal Revenue Code
S.5107, America's Clean Future Fund Act, Entirety Monitor the following: Public Law 117-169, Inflation Reduction Act, Carbon capture including Section 45Q carbon capture tax credits, and sustainable aviation fuel provisions; Hydrogen provisions including Section 45V clean hydrogen production tax credits; and Implementation 45Q inflation adjustment related issues H.R.1262/S.542, the CCU Parity Act, Entirety
Client expense: $40,000 · Firm income: Not reported
Government targets: SENATE
2024 · fourth_quarter · Taxation/Internal Revenue Code
Implementation of IIJA (PL 117-58) Implementation of IRA (PL 117-169) S. 542/ H.R. 1262, the CCU Parity Act of 2023
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Taxation/Internal Revenue Code
HR 1262 "CCU Parity Act of 2023" and S. 542 "CCU Parity Act of 2023."
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Taxation/Internal Revenue Code
45Q; Interest Deductibility; Highway Trust Fund Solvency; Capital Cost Recovery; Airport and Airway Trust Fund; Build It In America Act (H.R. 3938); Research & Development Tax Credit; CCUS Parity Act (HR 1262/S 542); Foreign Pollution Fee Act (S. 3198); Tax Relief for American Families and Workers Act of 2024 (H.R. 7024)
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Energy/Nuclear
- CCU Parity Act of 2023S. 542/H.R. 1262 Senate/House - Critical Mineral Independence Act of 2023S. 2031 Senate - Critical Minerals Security Act of 2024S. 3631/H.R. 7662 Senate/House - Inflation Reduction ActH.R. 5376 House/Senate/DOE/DOL - Infrastructure Investment and Jobs ActH.R. 3684 House/Senate/DOE/DOL - Intergovernmental Critical Minerals Task Force Act of 2023S. 1871 Senate - Lower Energy Costs ActH.R. 1 House - Mining Schools Act of 2023S. 912 Senate - North American Transatlantic Resource Security Partnership Act of 2023 - S. 458 Senate - ONSHORE Manufacturing Act of 2023S. 44 Senate - PROVE IT Act of 2024S. 1863/H.R. 8623 Senate/House - Permitting for Mining Needs Act of 2023H.R. 209 House - Securing American Critical Minerals Act of 2023H.R. 5021 House - Securing Americas Critical Minerals Supply ActH.R. 1068 House - Supply Chain Security and Resilience ActH.R. 826 House - Supply CHAINS ActH.R. 763 House - UMWA Energy Transition Initiative No Bill# Senate/House
Client expense: $80,817 · Firm income: Not reported
Government targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
2024 · third_quarter · Taxation/Internal Revenue Code
Implementation of IIJA (PL 117-58) Implementation of IRA (PL 117-169) S. 542/ H.R. 1262, the CCU Parity Act of 2023
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Taxation/Internal Revenue Code
Issues related to permitting, infrastructure, and sustainability; draft legislation regarding alternative fuels, building and construction materials standards, carbon capture and sequestration technology, and carbon pricing. S.1863, PROVE IT Act of 2023; S.542/H.R.1262 CCU Parity Act of 2023; S.3198 Foreign Pollution Fee Act of 2023; S.3439, Concrete and Asphalt Innovation Act; H.R.7685, IMPACT Act.
Client expense: Not reported · Firm income: $100,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Environment/Superfund
Issues related to permitting, infrastructure, and sustainability; draft legislation regarding alternative fuels, building and construction materials standards, carbon capture and sequestration technology, and carbon pricing. S.1863, PROVE IT Act of 2023; S.542/H.R.1262 CCU Parity Act of 2023; S.3198 Foreign Pollution Fee Act of 2023; S.3439, Concrete and Asphalt Innovation Act; H.R.7685, IMPACT Act.
Client expense: Not reported · Firm income: $100,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Clean Air and Water (quality)
Issues related to permitting, infrastructure, and sustainability; draft legislation regarding alternative fuels, building and construction materials standards, carbon capture and sequestration technology, and carbon pricing. S.1863, PROVE IT Act of 2023; S.542/H.R.1262 CCU Parity Act of 2023; S.3198 Foreign Pollution Fee Act of 2023; S.3439, Concrete and Asphalt Innovation Act; H.R.7685, IMPACT Act.
Client expense: Not reported · Firm income: $100,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Manufacturing
Issues related to permitting, infrastructure, and sustainability; draft legislation regarding alternative fuels, building and construction materials standards, carbon capture and sequestration technology, and carbon pricing. S.1863, PROVE IT Act of 2023; S.542/H.R.1262 CCU Parity Act of 2023; S.3198 Foreign Pollution Fee Act of 2023; S.3439, Concrete and Asphalt Innovation Act; H.R.7685, IMPACT Act.
Client expense: Not reported · Firm income: $100,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Natural Resources
Carbon dioxide supply chain and life cycle assessment issues; implementation of the Inflation Reduction Act section 45Q regarding CO2 sequestration; Carbon Capture Utilization Parity Act of 2023 (H.R. 1262 and S. 5402); lifecycle analysis of carbon dioxide utilization.
Client expense: Not reported · Firm income: $70,000
Government targets: Energy, Dept of, Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE, Treasury, Dept of
2024 · third_quarter · Taxation/Internal Revenue Code
Issues related to corporate and international tax; Issues related to the Section 45Q tax credit; S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act of 2023; S. 542/H.R. 1262 Captured Carbon Utilization Parity Act; H.R. 7024, Tax Relief for American Families and Workers Act of 2024.
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Taxation/Internal Revenue Code
Public Law 117-169, Inflation Reduction Act, Carbon capture including Section 45Q carbon capture tax credits, and sustainable aviation fuel provisions; Hydrogen provisions including Section 45V clean hydrogen production tax credits; and Implementation 45Q inflation adjustment related issues H.R.1262/S.542, the CCU Parity Act, Entirety
Client expense: $40,000 · Firm income: Not reported
Government targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Energy/Nuclear
Implementation of the Infrastructure Investment and Jobs Act (P.L.117-58) and the Inflation Reduction Act of 2022 (P.L.117-169); S.542/H.R.1262, CCU Parity Act of 2023; hydrogen energy production and tax issues.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2024 · third_quarter · Taxation/Internal Revenue Code
Implementation of the Infrastructure Investment and Jobs Act (P.L.117-58) and the Inflation Reduction Act of 2022 (P.L.117-169); S.542/H.R.1262, CCU Parity Act of 2023; hydrogen energy production and tax issues.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2024 · third_quarter · Environment/Superfund
Issues related to sustainable packaging and circular economy, including collection, recycling, end-market development, and claims, including S. 1194 / H.R. 4040 Recycling and Composting Accountability Act and S. 1189 Recycling Infrastructure and Accessibility Act of 2023 / Truth in Labeling Act (Discussion Draft). Issues related to carbon dioxide capture and utilization for food and beverage applications, including S. 542 / H.R. 1262 The Carbon Capture Utilization Parity Act. Issues related to renewable energy permitting including S. 4753 The Energy Permitting Reform Act.
Client expense: $120,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Taxation/Internal Revenue Code
45Q; Interest Deductibility; Highway Trust Fund Solvency; Capital Cost Recovery; Airport and Airway Trust Fund; Build It In America Act (H.R. 3938); Research & Development Tax Credit; CCUS Parity Act (HR 1262/S 542); Foreign Pollution Fee Act (S. 3198); Tax Relief for American Families and Workers Act of 2024 (H.R. 7024)
Client expense: $200,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Taxation/Internal Revenue Code
Implementation of 45Q tax credit for carbon dioxide utilization; S. 5402/H.R. 1262, the CCU Parity Act; lifecycle analysis of carbon dioxide utilization.
Client expense: $70,000 · Firm income: Not reported
Government targets: Energy, Dept of, SENATE
2024 · third_quarter · Taxation/Internal Revenue Code
HR 1262 "CCU Parity Act of 2023" and S. 542 "CCU Parity Act of 2023."
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Energy/Nuclear
- Accessing Americas Critical Minerals Act of 2021 H.R. 2604 House - Chips and Science Act H.R. 4346 House/Senate/DOE/DOL - CCU Parity Act of 2023 S. 542/H.R. 1262 Senate/House - Critical Mineral Independence Act of 2023 S. 2031 Senate - Critical Minerals Security Act of 2024 S. 3631/H.R. 7662 Senate/House - Inflation Reduction Act H.R. 5376 House/Senate/DOE/DOL - Infrastructure Investment and Jobs Act H.R. 3684 House/Senate/DOE/DOL - Lower Energy Costs Act H.R. 1 House - Mercury Air Toxins Standards No Bill# EPA/Senate/House - Mining Schools Act of 2023 S. 912 Senate - North American Transatlantic Resource Security Partnership Act of 2023 S. 458 Senate - ONSHORE Manufacturing Act of 2023 S. 44 Senate - Permitting for Mining Needs Act of 2023 H.R. 209 House - Securing American Critical Minerals Act of 2023 H.R. 5021 House - Securing Americas Critical Minerals Supply Act H.R. 1068 House - Supply Chain Security and Resilience Act H.R. 826 House - Supply CHAINS Act H.R. 763 House - UMWA Energy Transition Initiative No Bill# Senate/House
Client expense: $109,043 · Firm income: Not reported
Government targets: Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
2024 · second_quarter · Taxation/Internal Revenue Code
Implementation of IIJA (PL 117-58) Implementation of IRA (PL 117-169) S. 542/ H.R. 1262, the CCU Parity Act of 2023
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Environment/Superfund
Issues related to permitting, infrastructure, and sustainability; draft legislation regarding alternative fuels, building and construction materials standards, carbon capture and sequestration technology, and carbon pricing. S.1863, PROVE IT Act of 2023; S.542/H.R.1262 CCU Parity Act of 2023; S.3198 Foreign Pollution Fee Act of 2023; S.3439, Concrete and Asphalt Innovation Act; H.R.7685, IMPACT Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Taxation/Internal Revenue Code
Issues related to permitting, infrastructure, and sustainability; draft legislation regarding alternative fuels, building and construction materials standards, carbon capture and sequestration technology, and carbon pricing. S.1863, PROVE IT Act of 2023; S.542/H.R.1262 CCU Parity Act of 2023; S.3198 Foreign Pollution Fee Act of 2023; S.3439, Concrete and Asphalt Innovation Act; H.R.7685, IMPACT Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE